There are three approved BsAbs: Catumaxomab that can bring T cells or T lymphocytes via CD3 binding closer to cells expressing EpCAM (Trion Pharma); blinatumomab that also has a CD3-binding arm to B lymphomas with CD19(Micromet/Amgen); and Helimbra or emicizumab-kxwh (Roche—Chugai) that mimics the cofactor VIII for patients with hemophilia A. Catumaxomab is produced using quadroma technology where the HC and LC fragment of mouse mAbs against CD3 and rat mAbs against EpCAM were secreted by fusing the respective hybridomas to form a BsAb with an intact Fc. Here, EPCAM is linked to hemophilia A.